Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CANVAC DHPL is a multivalent veterinary vaccine developed by Dyntec for the active immunization of dogs starting from 8 weeks of age. The vaccine is designed to provide broad protection against four major canine pathogens: Canine Distemper Virus (D), Canine Adenovirus (H, specifically type 2 which cross-protects against type 1/infectious hepatitis), Canine Parvovirus (P), and Leptospira interrogans (L). It is typically supplied as a two-component system consisting of a lyophilized pellet containing live attenuated viral strains (CDV, CAV-2, and CPV) and a liquid solvent containing inactivated Leptospira serovars (icterohaemorrhagiae and canicola). Vaccination with CANVAC DHPL helps reduce clinical signs, viral shedding, and mortality associated with these common and potentially fatal canine infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CANVAC DHPL.